PBCI | Clinical Trials

Clinical Trials

The Palm Beach Cancer Institute actively participates in clinical research studies involving investigational drugs and treatment protocols, allowing its patients to gain access to innovative therapies. Current research studies include treatments for ovarian cancer, metastatic colon cancer, breast cancer, lung cancer, lymphoma and melanoma. PBCI engages in National Cancer Institute-sponsored trials through the Cancer and Leukemia Group B as an affiliate of Duke University, and participates in pharmaceutical and drug development research that offers protocols for a variety of diseases.

Choosing to participate in a clinical trial is an important personal decision. To learn some general information (FAQs) about clinical trials, click here. To learn more about the clinical trials offered at the Palm Beach Cancer Institute, please click on the links below or contact the Research Nurse at 561-366-4128.

Breast Cancer:
CALGB 40101 - Cyclophosphamide and Doxorubicin (CA 4 vs 6 cycles) versus Paclitaxel (4 vs 6 cycles) as Adjuvant Therapy for Women with Node-Negative Breast Cancer: A 2x2 Factorial Phase III Randomized Study

DCRO-BR-2006-03 - A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single Agent Chemotherapy to Treat Patients With Breast Cancer Metastatic to the Brain

DCRO-BR-2006-01 - A Phase II Study of Abraxane, Carboplatin and Bevacizumab in “Triple Negative” (Demonstrating No Expression For Estrogen, Progesterone or HER2 Receptors) Metastatic Breast Cancer Patients

RTA 744-C-0703 - A Phase II Efficacy and Tolerability Study of RTA 744 in Breast Cancer Patients with Progression of Previously Irradiated Brain Metastases

DCRO-BR-2006-02/BMS CA180089 - A Phase II Trial of Dasatinib to Treat Women With Stage IV or Inoperable Stage III Advanced Breast Cancer

Femara REAL - Phase IV, Open-label, multi-center study to evaluate the rheumatological tolerability of Femara® (letrozole) as an adjuvant Breast Cancer treatment in postmenopausal women who are intolerant to Arimidex® (anastrozole) due to arthralgias-myalgias.

BETH (CIRG 011/NSABP B-44) - A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab.

Aplastic Anemia/MDS:
P06-001 (EXPLORE) PNH - EXamination of PNH, by Level Of CD59 on Red and white blood cells, in bone marrow failure syndromes (EXPLORE). Please contact Research Nurse at 561-366-4128.

AVIDA (Vidaza) Registry - A prospective, multi-center, observational study compiling data on the natural history and management of patients diagnosed with myelodysplastic (MDS) and other hematological disorders undergoing Vidaza® (azacitidine) treatment.

Lymphoma:
BO20603 - A multi-center, randomized, double-blind, placebo-controlled Phase III trial comparing the efficacy of Bevacizumab in combination with Rituximab and CHOP (RA-CHOP) versus Rituximab and CHOP (R-CHOP) in previously untreated patients with CD20-positive diffuse large B-cell lymphoma (DLBCL)

Respiratory:
New Clinical trial coming soon.

Colon — Gastro-Intestinal:
N0147 - A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer

Multiple Myeloma:
AVF4064g - A Randomized, Blinded, Placebo-Controlled, Multicenter, Phase II Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

Melanoma:
New clinical trial coming soon.

Endometrial:
GOG-0209 - Randomized, Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel And G-CSF Versus Carboplatin/Paclitaxel In Patients With Stage III & IV Or Recurrent Endometrial Cancer

GOG-0210 - A Molecular Staging Study of Endometrial Cancer

Ovarian:
GOG-0212 - A Randomized, Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax™ (CT-2103) (IND# 70177) Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian or Primary Peritoneal Cancer Who Achieve A Complete Clinical Response To Primary Platinum/Taxane Chemotherapy

GOG-0218 - A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin And Paclitaxel Plus Concurrent Bevacizumab (NSC #704865, IND #7921) Followed By Placebo, Versus Carboplatin And Paclitaxel Plus Concurrent And Extended Bevacizumab, In Women With Newly Diagnosed, Previously Untreated, Stage III or IV, Epithelial Ovarian Or Primary Peritoneal Cancer.